Rare COVID Vaccine Clotting Linked to Adenoviral Protein - Summary - MDSpire

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

  • May 12, 2026

Share

Objective:

To identify the molecular trigger behind the rare clotting disorder linked to adenovirus-based COVID-19 vaccines.

Key Findings:
  • Identified adenoviral core protein VII (pVII) as the likely inciting antigen for VITT.
  • Antibodies against pVII matched the anti-PF4 antibody fingerprint seen in VITT.
  • Nearly all patients carried the same immunoglobulin light-chain variant with a specific mutation (K31E).
  • Reversing the K31E mutation reduced PF4 binding and clot-promoting activity.
Interpretation:

The study reveals that a normal immune response to adenovirus can, in rare cases, mistakenly target PF4, leading to clotting disorders.

Limitations:
  • Further studies are needed to assess the safety of modified adenoviral vaccines.
  • The rarity of VITT limits the sample size for comprehensive analysis.
Conclusion:

Modifying or removing the adenoviral protein pVII in future vaccines could prevent this rare clotting reaction while maintaining vaccine efficacy.

Original Source(s)

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

  • May 12, 2026

Related Content

Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published ...

Epcoritamab Plus R<sup>2</sup> in Follicular Lymphoma: A Potential New Treatment Standard

In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of di...